Interleukin-11 (Oprelvekin)
Stimulates the growth of multiple lymphoid and myeloid cells including primitive megakaryocytic progenitors, increases the number of peripheral platelets and neutrophils, approved for thrombocytopenia in patients receiving cytotoxic chemotherapy for treatment of non-myeloid cancers
Interleukin-11 (IL-11) is a cytokine or signaling molecule that plays an important role in various physiological processes such as cell differentiation, proliferation, and survival. It belongs to the interleukin family of proteins and is produced by several different cell types, including bone marrow stromal cells, fibroblasts, and endothelial cells.
IL-11 binds to its receptor, IL-11R, which is expressed on a variety of cells throughout the body. This leads to a signaling cascade that ultimately promotes the growth and survival of various cell types, including platelets, osteoclasts, and immune cells.
Oprelvekin is a recombinant form of IL-11 that is used as a medication to stimulate platelet production in patients with low platelet counts. It was approved by the FDA in 1997 and is administered as an injection under the skin or into a vein.
Common side effects of Oprelvekin include fluid retention, fatigue, and joint pain. It should not be used in patients with a history of heparin-induced thrombocytopenia or in those with certain types of cancers such as myeloid malignancies. As with any medication, it is important to discuss the risks and benefits of treatment with a healthcare provider.
More Answers:
Role of Transcobalamin Protein in Vitamin B12 Transport and Its Significance For Health.Discovering the Cause of Vitamin B12 Malabsorption: Schilling Test
The Role of Romiplostim for Optimizing Platelet Counts in Chronic Immune Thrombocytopenia (ITP) Treatment